FR15C0047I1 - - Google Patents

Info

Publication number
FR15C0047I1
FR15C0047I1 FR15C0047C FR15C0047I1 FR 15C0047 I1 FR15C0047 I1 FR 15C0047I1 FR 15C0047 C FR15C0047 C FR 15C0047C FR 15C0047 I1 FR15C0047 I1 FR 15C0047I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0047(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0047I1 publication Critical patent/FR15C0047I1/fr
Application granted granted Critical
Publication of FR15C0047I2 publication Critical patent/FR15C0047I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
FR15C0047C 2002-04-16 2015-07-03 Antagonistes tricycliques du recepteur de thrombine Active FR15C0047I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
PCT/US2003/011510 WO2003089428A1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Publications (2)

Publication Number Publication Date
FR15C0047I1 true FR15C0047I1 (de) 2015-08-28
FR15C0047I2 FR15C0047I2 (fr) 2016-05-06

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0047C Active FR15C0047I2 (fr) 2002-04-16 2015-07-03 Antagonistes tricycliques du recepteur de thrombine

Country Status (34)

Country Link
US (3) US7304078B2 (de)
EP (5) EP2065384B1 (de)
JP (2) JP4558331B2 (de)
KR (1) KR101026929B1 (de)
CN (1) CN1659162B (de)
AR (1) AR039570A1 (de)
AT (3) ATE378330T1 (de)
AU (1) AU2003221932B2 (de)
BR (1) BRPI0309309B8 (de)
CA (1) CA2482858C (de)
CY (3) CY1107184T1 (de)
DE (3) DE60331114D1 (de)
DK (2) DK1495018T3 (de)
EC (1) ECSP045368A (de)
ES (3) ES2338171T3 (de)
FR (1) FR15C0047I2 (de)
HK (3) HK1070887A1 (de)
IL (1) IL164585A (de)
LT (1) LTC1495018I2 (de)
LU (1) LU92759I2 (de)
MX (1) MXPA04010308A (de)
MY (1) MY144040A (de)
NL (1) NL300746I2 (de)
NO (2) NO330500B1 (de)
NZ (2) NZ575139A (de)
PE (1) PE20040412A1 (de)
PL (1) PL214718B1 (de)
PT (2) PT2065384E (de)
RU (2) RU2329264C9 (de)
SG (1) SG164279A1 (de)
SI (2) SI2065384T1 (de)
TW (1) TWI343919B (de)
WO (1) WO2003089428A1 (de)
ZA (1) ZA200408342B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
JP4558788B2 (ja) * 2004-05-28 2010-10-06 シェーリング コーポレイション トロンビンレセプターアンタゴニストとしての条件付きヒンバシンアナログ
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
SG158884A1 (en) * 2005-01-14 2010-02-26 Schering Corp An exo-selective synthesis of himbacine analogs
PT1848705E (pt) 2005-01-14 2010-05-10 Schering Corp Sínteses exo- e diastereo-selectivas de análogos da himbacina
US20060172397A1 (en) * 2005-01-14 2006-08-03 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
PT1853592E (pt) * 2005-01-14 2011-05-10 Schering Corp S?ntese de an?logos da himbacina
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
EP1863778B1 (de) 2005-03-31 2015-12-30 Merck Sharp & Dohme Corp. Spirocyclische thrombinrezeptorantagonisten
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
EP1971336A2 (de) * 2005-12-22 2008-09-24 Shering Corporation Thrombin-rezeptor-antagonisten zur prophylaxe vor komplikationen einer kardiopulmonalen operation
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
EP2266976B1 (de) * 2006-04-13 2013-07-31 Merck Sharp & Dohme Corp. Fusionierte Ring-Thrombinrezeptorantagonisten
AU2007269830A1 (en) * 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
EP2069326B1 (de) * 2006-10-04 2015-03-18 Merck Sharp & Dohme Corp. Bizyklische und trizyklische derivate als thrombin-rezeptor-antagonisten
AU2007320029A1 (en) * 2006-10-04 2008-05-22 Schering Corporation Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
WO2008118320A1 (en) * 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist
KR20100120139A (ko) 2008-02-05 2010-11-12 사노피-아벤티스 Ｐａｒ１ 억제제로서의 트리아졸륨 염, 이들의 제조방법, 및 약제로서의 용도
KR20100114514A (ko) 2008-02-05 2010-10-25 사노피-아벤티스 Ｐａｒ１ 억제제로서의 트리아졸로피리다진, 이의 제조방법 및 약제로서의 용도
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
CL2009001214A1 (es) 2008-05-19 2010-12-31 Schering Corp Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos
SI2438060T1 (sl) * 2009-06-04 2014-04-30 Merck Sharp & Dohme Corp. Aktivni metabolit trombin receptorskega antagonista
EP2440191A2 (de) 2009-06-08 2012-04-18 Schering Corporation Tablette mit einer fixen dosis eines thrombin-rezeptor-antagonisten und clopidogrel
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
PL2558465T3 (pl) 2010-04-16 2015-05-29 Sanofi Sa Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1)
PL2558462T3 (pl) 2010-04-16 2015-03-31 Sanofi Sa Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015013083A1 (en) * 2013-07-22 2015-01-29 Merck Sharp & Dohme Corp. Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
EP3035930A4 (de) * 2013-08-22 2017-03-08 Merck Sharp & Dohme Corp. 7a-heterocyclus-substituierte 6,6-difluor-bicyclus-himbacinderivate
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
CN107304200B (zh) * 2016-04-22 2021-09-21 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
EP4185587A1 (de) 2020-07-22 2023-05-31 JANSSEN Pharmaceutica NV Verbindungen als faktor-xia-hemmer
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
ID24726A (id) * 1997-11-25 2000-08-03 Schering Corp Antagonis-antagonis reseptor trombin
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
SK287026B6 (sk) 2000-06-15 2009-10-07 Schering Corporation Nor-seko-himbacínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
JP4307260B2 (ja) * 2001-10-18 2009-08-05 シェーリング コーポレイション トロンビンレセプタアンタゴニストとしてのヒンバシン類似物

Also Published As

Publication number Publication date
KR20040099441A (ko) 2004-11-26
AU2003221932B2 (en) 2007-11-22
JP4558331B2 (ja) 2010-10-06
US20070270439A1 (en) 2007-11-22
US7304078B2 (en) 2007-12-04
CA2482858A1 (en) 2003-10-30
DK1495018T3 (da) 2008-02-18
PL373332A1 (en) 2005-08-22
CY1107184T1 (el) 2012-10-24
US7713999B2 (en) 2010-05-11
BR0309309A (pt) 2005-02-15
NO2015016I2 (no) 2015-07-09
AR039570A1 (es) 2005-02-23
PT1495018E (pt) 2008-02-19
SI2065384T1 (sl) 2011-05-31
PL214718B1 (pl) 2013-09-30
EP2065384B1 (de) 2011-01-05
CY2015029I2 (el) 2016-04-13
EP1982984A3 (de) 2008-10-29
ZA200408342B (en) 2006-05-31
ATE494284T1 (de) 2011-01-15
IL164585A (en) 2010-11-30
NO20044963L (no) 2004-11-15
WO2003089428A1 (en) 2003-10-30
DE60317493T3 (de) 2018-07-12
RU2329264C2 (ru) 2008-07-20
BRPI0309309B8 (pt) 2021-05-25
KR101026929B1 (ko) 2011-04-04
BRPI0309309B1 (pt) 2018-09-04
US20030216437A1 (en) 2003-11-20
JP2010132710A (ja) 2010-06-17
NL300746I1 (de) 2016-01-21
MXPA04010308A (es) 2005-02-03
SG164279A1 (en) 2010-09-29
DE60317493T2 (de) 2008-09-18
NZ535880A (en) 2007-11-30
FR15C0047I2 (fr) 2016-05-06
NO2015016I1 (no) 2015-07-20
CA2482858C (en) 2010-11-30
ES2357876T3 (es) 2011-05-03
IL164585A0 (en) 2005-12-18
EP1860106A1 (de) 2007-11-28
HK1070887A1 (en) 2005-06-30
NO330500B1 (no) 2011-05-02
ATE378330T1 (de) 2007-11-15
RU2329264C9 (ru) 2009-04-20
ES2338171T3 (es) 2010-05-04
CY1111363T1 (el) 2015-08-05
DE60317493D1 (en) 2011-01-13
MY144040A (en) 2011-07-29
EP2065384A1 (de) 2009-06-03
ECSP045368A (es) 2005-01-03
DK2065384T3 (da) 2011-05-02
HK1129893A1 (en) 2009-12-11
DE60331114D1 (de) 2010-03-11
EP1495018B3 (de) 2011-03-16
HK1123302A1 (en) 2009-06-12
EP2062890B1 (de) 2011-01-05
PE20040412A1 (es) 2004-07-12
TW200404068A (en) 2004-03-16
CY2015029I1 (el) 2016-04-13
DE60335679D1 (de) 2011-02-17
EP1982984B1 (de) 2013-02-13
AU2003221932A1 (en) 2003-11-03
CN1659162B (zh) 2011-08-31
CN1659162A (zh) 2005-08-24
LU92759I2 (en) 2015-08-31
PT2065384E (pt) 2011-03-16
US20070179187A1 (en) 2007-08-02
RU2004133375A (ru) 2005-07-10
JP2005528406A (ja) 2005-09-22
ES2297150T7 (es) 2012-03-16
TWI343919B (en) 2011-06-21
EP1860106B1 (de) 2010-01-20
ATE455774T1 (de) 2010-02-15
EP1495018A1 (de) 2005-01-12
EP1982984A2 (de) 2008-10-22
LTC1495018I2 (lt) 2017-04-10
EP2062890A1 (de) 2009-05-27
SI1495018T1 (sl) 2008-04-30
NZ575139A (en) 2010-08-27
ES2297150T3 (es) 2008-05-01
RU2008106401A (ru) 2009-08-27
NL300746I2 (de) 2016-01-21
EP1495018B1 (de) 2007-11-14

Similar Documents

Publication Publication Date Title
BE2019C547I2 (de)
BE2019C510I2 (de)
BE2018C021I2 (de)
BE2017C049I2 (de)
BE2017C005I2 (de)
BE2016C069I2 (de)
BE2016C040I2 (de)
BE2018C018I2 (de)
BE2016C002I2 (de)
BE2015C078I2 (de)
FR15C0047I1 (de)
BE2015C017I2 (de)
BE2014C053I2 (de)
BE2014C051I2 (de)
BE2014C041I2 (de)
BE2014C030I2 (de)
BE2014C016I2 (de)
BE2014C015I2 (de)
BE2013C063I2 (de)
BE2013C039I2 (de)
BE2011C038I2 (de)
JP2003182329A5 (de)
JP2003234757A5 (de)
BE2013C046I2 (de)
JP2003224106A5 (de)